H.C. Wainwright raised the firm’s price target on Cidara Therapeutics (CDTX) to $110 from $74 and keeps a Buy rating on the shares after the company announced that the first patients have been in dosed in its registrational Phase 3 ANCHOR study evaluating CD388 for the prevention of seasonal influenza. With the expanded patient population, which brings the initial addressable target population from 50M to over 100M in the U.S. alone, the market opportunity for CD388 continues to strengthen, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDTX:
- Cidara Therapeutics doses first patient in CD388 trial
- Cidara Therapeutics Expands Phase 3 Trial for CD388
- Cidara Therapeutics price target raised to $153 from $66 at Citizens JMP
- Cidara Therapeutics price target raised to $100 from $74 at Needham
- Cidara Therapeutics’ Accelerated Path to BLA Approval and Expanded Market Potential Boosts Buy Rating